×
About 4,908 results

ALLMedicine™ Astrocytoma Center

Research & Reviews  1,707 results

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

Hypertrophic Olivary Degeneration Postoperatively Following Pilocytic Astrocytoma Resec...
https://doi.org/10.1016/j.wneu.2022.06.045
World Neurosurgery; McDonald MF, Rao G et. al.

Jun 20th, 2022 - A 25-year-old male presented with headaches 3 weeks after a car accident. His MRI images showed a hemorrhagic vermis mass with 4th ventricle effacement. One month later, he underwent suboccipital craniotomy for removal of a pilocytic astrocytoma. ...

CLINICAL AND HISTOPATHOLOGICAL FINDINGS OF HEMORRHAGIC ASCENDING AND DESCENDING PROGRES...
https://doi.org/10.1016/j.tcam.2022.100681
Topics in Companion Animal Medicine; Schwab ML, Ferrarin DA et. al.

Jun 20th, 2022 - Bichon Frise (1) and Boxer (2), both with epileptic seizures, underwent lumbar taps for cerebrospinal fluid collection. After the examination, the first dog became paraplegic, and the second dog did not recover from anesthesia and remained in a co...

see more →

Guidelines  3 results

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.

Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...

The role of initial chemotherapy for the treatment of adults with diffuse low grade gli...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.

Nov 5th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...

The role of surgery in the management of patients with diffuse low grade glioma: A syst...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.

Nov 5th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...

see more →

Drugs  33 results see all →

Clinicaltrials.gov  139 results

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04047303

Jun 14th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...

Low Dose Radiation Therapy for Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT01466686

Jun 13th, 2022 - In vitro and in vivo studies have suggested that low dose fractionated radiation therapy (LDFRT) may be used to potentiate full dose chemotherapy, decreasing the development of resistance found with standard doses of radiation and chemotherapy. Th...

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT04757662

Jun 10th, 2022 - Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of treatment resistance...

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT03528642

Jun 8th, 2022 - PRIMARY OBJECTIVE: I. Determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of telaglenastat (CB-839) hydrochloride (HCl) when combined with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagn...

see more →

News  79 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Net Guides: Childhood Tumors
https://www.onclive.com/view/net-guides-childhood-tumors

Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...

Brain Tumors Exact Higher Mortality Toll in Men Than Women
https://www.medscape.com/viewarticle/968594

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors

Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...

see more →

Patient Education  2 results see all →